Background illustration for clinical trials search

Lung Cancer Clinical Trials

Browse 2,144 lung cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

A Study of DM005 in Patients With Advanced Solid Tumors

for
Carcinoma, Non-Small-Cell Lung,
Location: Fairfax VA, Detroit MI, Dallas TX
Sponsor: Doma Biopharmaceutical(Suzhou)Co., Ltd.

Sex: All

Age: 18+

Code: NCT06515990

Phase 1, Phase 2, Recruiting
Active & Responsive

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

for
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer,
Location: Dothan AL, Grand Rapids MI, Omaha NE, Houston TX
Sponsor: Radiopharm Theranostics, Ltd

Sex: All

Age: 18+

Code: NCT07189871

Phase 1, Phase 2, Recruiting
Active & Responsive

Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Sex: All

Age: 18+

Code: NCT06743581

Recruiting
Active & Responsive

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, New York NY,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07111520

Phase 1, Phase 2, Recruiting
Active & Responsive

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

for
Prostate Cancer Castration-resistant Prostate Cancer,
Location: East Brunswick NJ, Fairfax VA, Grand Rapids MI,
Sponsor: MBrace Therapeutics

Sex: All

Age: 18+

Code: NCT07145255

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

for
Non Small Cell Lung Cancer
Location: New York NY, Philadelphia PA, Coral Gables FL,
Sponsor: Ankyra Therapeutics, Inc

Sex: All

Age: 18+

Code: NCT07027514

Phase 1, Recruiting
Active & Responsive

DBC-664 in Adult Patients With Solid Tumors

for
Malignant Germ Cell Tumor, Lung Adenocarcinoma,
Location: Lake Success NY, East Brunswick NJ, Grand Rapids MI,
Sponsor: Duboce Biopharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07705035

Phase 1, Recruiting
Active & Responsive

GCC 2546- Motion Management

for
Lung Cancer (NSCLC), Radiation
Location: Baltimore MD
Sponsor: University of Maryland, Baltimore

Sex: All

Age: 18+

Code: NCT07398209

Recruiting
Active & Responsive

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

for
Small Cell Lung Cancer ( SCLC ),
Location: Indianapolis IN
Sponsor: Misty Shields

Sex: All

Age: 18+

Code: NCT07153055

Phase 1, Phase 2, Recruiting
Active & Responsive

A 2-part Phase 1/2 Open-label Trial on ODM-212

for
Mesothelioma, Pancreatic Cancer,
Location: Fairfax VA, Irving TX, Fort Worth TX, Orange CA,
Sponsor: Orion Corporation, Orion Pharma

Sex: All

Age: 18+

Code: NCT07563738

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

for
Triple Negative Breast Cancer, HER2-negative Breast Cancer,
Location: Fairfax VA, Orlando FL, Huntersville NC, Sarasota FL,
Sponsor: Dren Bio

Sex: All

Age: 18+

Code: NCT06999187

Phase 1, Recruiting
Active & Responsive

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

for
Carcinoma, Non-Small Cell Lung
Location: Baltimore MD, Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 18+

Code: NCT04499053

Phase 2, Recruiting
Active & Responsive

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

for
Pleuropulmonary Blastoma
Location: Halifax, Boston MA, Quebec, Sherbrooke,
Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 21

Code: NCT06647953

Phase 3, Recruiting
Active & Responsive

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

for
Carcinoma, Non-Small-Cell Lung
Location: Lebanon NH, Philadelphia PA, Columbus OH, Houston TX,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04165798

Recruiting
Active & Responsive

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

for
Extensive Stage-small Cell Lung Cancer
Location: Lebanon NH, Mineola NY, New York NY, Hackensack NJ,
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06362252

Phase 1, Phase 2, Recruiting
Active & Responsive

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

for
Non-small Cell Lung Cancer, NSCLC
Location: Hackensack NJ, Trois-Rivieres, Pennington NJ, Montreal,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06422143

Phase 3, Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

for
Anatomic Stage III Breast Cancer AJCC v8,
Location: Jacksonville FL
Sponsor: Mayo Clinic

Sex: All

Age: 16+

Code: NCT05269381

Phase 1, Phase 2, Recruiting

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

for
Clinical Stage III Cutaneous Melanoma AJCC v8,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06075524

Recruiting

Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis

for
Hemoptysis, Haemoptysis, Lung Disease, Pneumonia, Tuberculosis,
Location: Sherbrooke
Sponsor: Université de Sherbrooke

Sex: All

Age: 18+

Code: NCT02913365

Recruiting

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

for
Anatomic Stage IV Breast Cancer AJCC v8,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT04771520

Phase 2, Recruiting

What is lung cancer?

Lung cancer starts when cells in the airways or lungs grow out of control. About 229,000 Americans will be diagnosed in 2026. There are two main types: non small cell lung cancer, about 85 percent of cases, and small cell lung cancer, which grows and spreads faster and is treated differently. Smoking causes most cases, but 10 to 20 percent happen in people who never smoked, from causes like radon, air pollution, or genetic changes. Most people are diagnosed around age 70.

Two things changed treatment. First, many lung cancers are driven by a single gene change, and pills that target that specific change can control the cancer for years, so tumors are now routinely tested for these changes before treatment starts. Second, immunotherapy works especially well in lung cancer, and some people with advanced disease are alive and well more than five years later. New targeted drugs kept getting approved through 2025, which is why lung cancer has more recruiting trials than any cancer except breast cancer.

Types of lung cancer clinical trials

Who can participate in lung cancer clinical trials?

What causes lung cancer?

Does vaping cause lung cancer?

The stages of lung cancer, and why they matter for trials

How to enroll in a lung cancer clinical trial